AI-driven 113-gene signature for T-AC therapy
Early-Stage Breast Cancer (Neoadjuvant)
Clinical ValidationActive
Key Facts
Indication
Early-Stage Breast Cancer (Neoadjuvant)
Phase
Clinical Validation
Status
Active
Company
About Aida Oncology
Aida Oncology is a private, pre-revenue diagnostics company leveraging machine learning on RNA expression data to predict chemotherapy efficacy, starting with taxanes in breast cancer. The company has presented multiple clinical validation studies at major conferences (ESMO 2025, SABCS) for its multigene signatures. Its business model targets the large, underserved market of chemotherapy selection, aiming to reduce ineffective treatments and improve patient outcomes.
View full company profile